Роль показателя времени нахождения в целевом диапазоне (Time in range) в зависимости от метода оценки гликемического контроля при сахарном диабете

1. IDF Diabetes Atlas, 10th edition. Brussels: International Diabetes Federation; 2021. Available at: https://www.diabetesatlas.org/data/en/world/. Accessed: 15.02.2022.
2. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Атлас регистра сахарного диабета Российской Федерации. Статус 2018 г. Сахарный диабет. 2019;22(2S):4-61 [Dedov II, Shestakova MV, Vikulova OK, et al. Atlas of Diabetes Register in Russian Federation, status 2018. Saharnyj diabet. 2019;22(2S):4-61 (in Russian)]. DOI:10.14341/DM12208
3. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204-21 [Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Saharnyj diabet. 2021;24(3):204-21 (in Russian)]. DOI:10.14341/DM12759
4. Сахарный диабет 1 типа у взрослых: клинические рекомендации. Утв. Минздравом России. Российская ассоциация эндокринологов. Судебные и нормативные акты РФ. 2019. Режим доступа: https://sudact.ru/law/klinicheskie-rekomendatsii-sakharnyi-diabet-1-tipa-u_1/klinicheskie-rekomendat.... Ссылка активна на 20.02.2022 [Type 1 diabetes mellitus in adults: clinical guidelines. Approved Ministry of Health of Russia. Russian Association of Endocrinologists. Judicial and normative acts of the Russian Federation. 2019. Available at: https://sudact.ru/law/klinicheskie-rekomendatsii-sakharnyi-diabet-1-tipa-u_1/klinicheskie-rekomendat.... Accessed: 20.02.2022 (in Russian)].
5. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44:2589-625. DOI:10.1007/s00125-021-05568-3 
6. Dattatreya A, Sarangi T. A Review on Diabetes Mellitus: Complications, Management and Treatment Modalities. Research & Reviews: Journal of Medical and Health Sciences. 2015. Available at: https://www.rroij.com/open-access/diabetic-complications-their-treatment.php?aid=52788. Accessed: 20.02.2022.
7. Тарасов Ю.В., Филиппов Ю.И., Борисова Е.К., и др. Технологии непрерывного мониторирования глюкозы: успехи и перспективы. Проблемы эндокринологии. 2015;61(4):54‑72 [Tarasov YuV, Filippov IuI, Borisova EK, et al. Continuous glucose monitoring technologies: state of the art and future perspectives in view of artificial pancreas. Problemy Endokrinologii. 2015;61(4):54‑72 (in Russian)]. DOI:10.14341/probl201561454-72 
8. Демидова Т.Ю. Современные технологии непрерывного мониторинга гликемии : развивающиеся возможности контроля и управления. Российский медицинский журнал. 2018;11:86-90 [Demidova TJu. Modern technologies of continuous glucose monitoring: developing possibilities of control and management. Rossijskij medicinskij zhurnal. 2018;11:86-90 (in Russian)].
9. Kovatchev BP. Metrics for glycaemic control-from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;7(13):425-36. DOI:10.1038/nrendo.2017.3 
10. Шестакова М.В., Майоров А.Ю., Филиппов Ю.И., и др. Федеральные клинические рекомендации по помповой инсулинотерапии и непрерывному мониторированию гликемии у больных сахарным диабетом: утв. на VII Всероссийском диабетологическом конгрессе 28.02.2015. Режим доступа: https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pompa. Ссылка активна на 20.02.2022 [Shestakova MV, Mayorov AYu, Filippov YuI, et al. Federal clinical guidelines for insulin pump therapy and continuous monitoring of glycemia in patients with diabetes mellitus: approved. at the VII All-Russian Diabetology Congress on February 28, 2015. Available at: https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pompa. Accessed: 20.02.2022 (in Russian)].
11. Beers CAJ, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): 
a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;11(4):893-902. DOI:10.1016/S2213-8587(16)30193-0
12. Li F, Liu B, Zhu H, et al. Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men. J Diabetes Res. 2017;2017:2740372. DOI:10.1155/2017/2740372 
13. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск. Сахарный диабет. 2019;22(1S1):1-144 [Dedov II, Shestakova MV, Majorov AJu, et al. Standards of specialized diabetes care. 9th edition. Saharnyj diabet. 2019;22(1S1):1-144 (in Russian)]. DOI:10.14341/DM221S1 
14. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care. 2019;8(42):1593-603.
15. Ajjan RA. How can we realize the clinical benefits of continuous glucose monitoring? Diabetes Technol Ther. 2017;S2(19):S27-36. DOI:10.1089/dia.2017.0021 
16. Rodbard D. Metrics to Evaluate Quality of Glycemic Control: Comparison of Time in Target, Hypoglycemic, and Hyperglycemic Ranges with «risk Indices». Diabetes Technol Ther. 2018;5(20):325-34. DOI:10.1089/dia.2017.0416 
17. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;12(40):1631-40. DOI:10.2337/dc17-1600 
18. American Diabetes Association. 6 Glycemic targets: Standards of medical care in diabetes–2019. Diabetes Care. 2019;42(1):61-70. DOI:10.2337/dc19-S006 
19. Петунина Н.А., Гончарова Е.В., Панасенко О.И. Основные аспекты регулярного самоконтроля уровня гликемии у пациентов с сахарным диабетом. Кардиосоматика. 2018;1(9):61-6 [Petunina NA, Goncharova EV, Panasenko OI. The main aspects of regular self-monitoring of the level of glycemia in patients with diabetes mellitus. Kardiosomatika. 2018;1(9):61-6 (in Russian)].
20. Бирюкова Е.В., Платонова Н.М. Самоконтроль гликемии в лечении сахарного диабета: все ли мы знаем о современных возможностях? Справочник поликлинического врача. 2019;3:20-3 [Birjukova EV, Platonova NM. Self-control of glycemia in the treatment of diabetes mellitus: do we know everything about modern possibilities? Spravochnik poliklinicheskogo vracha. 2019;3:20-3 (in Russian)].
21. Blevins T. Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus. Postgrad Med. 2013;125(3):191-204. DOI:10.3810/pgm.2013.05.2668 
22. Parkin CG, Buskirk A, Hinnen DA, et al. Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(1):6-15. DOI:10.1016/j.diabres.2012.03.002
23. Mannucci E, Antenore A, Giorgino F, et al. Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. J Diabetes Sci Technol. 2018;12(1):183-9. DOI:10.1177/1932296817719290 
24. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2019;21(S1):S4-S12. DOI:10.1089/dia.2019.2501 
25. Nathan DM, Genuth S, Lachin J, et al; Diabetes Control and Complications Trial Research Group.The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications. New Engl J Med. 1993;329(14):977-86.
26. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: Results from the structured testing program study. Diabetes Care. 2011;2(34):262-7. DOI:10.2337/dc10-1732 
27. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400-5.
DOI:10.2337/dc18-1444 
28. Bergenstal RM. Presented at the American Diabetes Association, 80th Scientific Sessions. June 12–16, 2020. Poster 21-LB.
29. Бирюкова Е.В. Роль гликированного гемоглобина в диагностике и улучшении прогноза сахарного диабета. Медицинский совет. 2017;3:55-7 [Birjukova EV. The role of glycated hemoglobin in the diagnosis and improvement of the prognosis of diabetes mellitus. Medicinskij sovet. 2017;3:55-7 (in Russian)].
30. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care. 2014;37(1):9-16. DOI:10.2337/dc13-2112 
31. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation / WHO Guidelines Approved by the Guidelines Review Committee. Geneva: World Health Organization, 2011. Available at: https://pubmed.ncbi.nlm.nih.gov/26158184/ Accessed: 18.11.2021.
32. Hashimoto K, Osugi T, Noguchi S, et al. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care. 2010;33(3):509-11. DOI:10.2337/dc09-1954 
33. Inaba M, Okuno S, Kumeda Y, et al. Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896-903. DOI:10.1681/ASN.2006070772 
34. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153-63. 
35. Ford ES, Cowie CC, Li C, et al. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3(1):67-73.
DOI:10.1111/j.1753-0407.2010.00100.x
36. Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018;41(11):2370-6. DOI:10.2337/dc18-1131 
37. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. DOI:10.1136/bmjdrc-2019-000991 
38. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019;2(21):81-5. DOI:10.1089/dia.2018.0310 
39. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13(4):614-26. DOI:10.1177/1932296818822496 
40. Ohigashi M, Osugi K, Kusunoki Y, et al. Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol. J Diabetes Investig. 2021;12(6):940-9. DOI:10.1111/jdi.13437 
41. Yoo JH, Choi MS, Ahn J, et al. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes. Diabetes Technol Ther. 2020;22(10):768-76. DOI:10.1089/dia.2019 
42. Kim MY, Kim G, Park JY, et al. The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes. Diabetes Technol Ther. 2021;23(6):434-42. DOI:10.1089/dia.2020.0599 
43. Lu J, Ma X, Shen Y, et al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. Diabetes Technol Ther. 2020;22(2):72-8. DOI:10.1089/dia.2019.0251 
44. Sheng X, Xiong G-H, Yu P-F, et al. The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform. Int J Endocrinol. 2020;2020:8879085. DOI:10.1155/2020/8879085 
45. Avari P, Uduku C, George D, et al. Differences for Percentage Times in Glycemic Range between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset. Diabetes Technol Ther. 2020;3(22):222-7. DOI:10.1089/dia.2019.0276 
46. Beck RW, Calhoun P, Kollman C. Use of continuous glucose monitoring as an outcome measure in clinical trials. Diabetes Technol Ther. 2012;10(14):877-82. DOI:10.1089/dia.2012.0079 
47. Суплотова Л.А., Судницына А.С., Романова Н.В., и др. Анализ времени нахождения в целевом диапазоне в зависимости от метода оценки уровня глюкозы. Медицинский Совет. 2021;7:46-55 [Suplotova LA, Sudnicyna AS, Romanova NV. Analysis of time in range depending on the method of assessing the glucose level. Medicinskij Sovet. 2021;7:46-55 (in Russian)]. DOI:10.21518/2079-701X-2021-7-46-55 
48. Fiallo-Scharer R. Eight-point glucose testing Versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. J Clin Endocrinol Metab. 2005;90(6):3387-91. DOI:10.1210/jc.2004-2510 

________________________________________________

1. IDF Diabetes Atlas, 10th edition. Brussels: International Diabetes Federation; 2021. Available at: https://www.diabetesatlas.org/data/en/world/. Accessed: 15.02.2022.
2. Dedov II, Shestakova MV, Vikulova OK, et al. Atlas of Diabetes Register in Russian Federation, status 2018. Saharnyj diabet. 2019;22(2S):4-61 (in Russian). DOI:10.14341/DM12208
3. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Saharnyj diabet. 2021;24(3):204-21 (in Russian). DOI:10.14341/DM12759
4. Type 1 diabetes mellitus in adults: clinical guidelines. Approved Ministry of Health of Russia. Russian Association of Endocrinologists. Judicial and normative acts of the Russian Federation. 2019. Available at: https://sudact.ru/law/klinicheskie-rekomendatsii-sakharnyi-diabet-1-tipa-u_1/klinicheskie-rekomendat.... Accessed: 20.02.2022 (in Russian).
5. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44:2589-625. DOI:10.1007/s00125-021-05568-3 
6. Dattatreya A, Sarangi T. A Review on Diabetes Mellitus: Complications, Management and Treatment Modalities. Research & Reviews: Journal of Medical and Health Sciences. 2015. Available at: https://www.rroij.com/open-access/diabetic-complications-their-treatment.php?aid=52788. Accessed: 20.02.2022.
7. Tarasov YuV, Filippov IuI, Borisova EK, et al. Continuous glucose monitoring technologies: state of the art and future perspectives in view of artificial pancreas. Problemy Endokrinologii. 2015;61(4):54‑72 (in Russian). DOI:10.14341/probl201561454-72 
8. Demidova TJu. Modern technologies of continuous glucose monitoring: developing possibilities of control and management. Rossijskij medicinskij zhurnal. 2018;11:86-90 (in Russian).
9. Kovatchev BP. Metrics for glycaemic control-from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;7(13):425-36. DOI:10.1038/nrendo.2017.3 
10. Shestakova MV, Mayorov AYu, Filippov YuI, et al. Federal clinical guidelines for insulin pump therapy and continuous monitoring of glycemia in patients with diabetes mellitus: approved. at the VII All-Russian Diabetology Congress on February 28, 2015. Available at: https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pompa. Accessed: 20.02.2022 (in Russian).
11. Beers CAJ, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): 
a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;11(4):893-902. DOI:10.1016/S2213-8587(16)30193-0
12. Li F, Liu B, Zhu H, et al. Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men. J Diabetes Res. 2017;2017:2740372. DOI:10.1155/2017/2740372 
13. Dedov II, Shestakova MV, Majorov AJu, et al. Standards of specialized diabetes care. 9th edition. Saharnyj diabet. 2019;22(1S1):1-144 (in Russian). DOI:10.14341/DM221S1 
14. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care. 2019;8(42):1593-603.
15. Ajjan RA. How can we realize the clinical benefits of continuous glucose monitoring? Diabetes Technol Ther. 2017;S2(19):S27-36. DOI:10.1089/dia.2017.0021 
16. Rodbard D. Metrics to Evaluate Quality of Glycemic Control: Comparison of Time in Target, Hypoglycemic, and Hyperglycemic Ranges with «risk Indices». Diabetes Technol Ther. 2018;5(20):325-34. DOI:10.1089/dia.2017.0416 
17. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;12(40):1631-40. DOI:10.2337/dc17-1600 
18. American Diabetes Association. 6 Glycemic targets: Standards of medical care in diabetes–2019. Diabetes Care. 2019;42(1):61-70. DOI:10.2337/dc19-S006 
19. Petunina NA, Goncharova EV, Panasenko OI. The main aspects of regular self-monitoring of the level of glycemia in patients with diabetes mellitus. Kardiosomatika. 2018;1(9):61-6 (in Russian).
20. Birjukova EV, Platonova NM. Self-control of glycemia in the treatment of diabetes mellitus: do we know everything about modern possibilities? Spravochnik poliklinicheskogo vracha. 2019;3:20-3 (in Russian).
21. Blevins T. Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus. Postgrad Med. 2013;125(3):191-204. DOI:10.3810/pgm.2013.05.2668 
22. Parkin CG, Buskirk A, Hinnen DA, et al. Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(1):6-15. DOI:10.1016/j.diabres.2012.03.002
23. Mannucci E, Antenore A, Giorgino F, et al. Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. J Diabetes Sci Technol. 2018;12(1):183-9. DOI:10.1177/1932296817719290 
24. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2019;21(S1):S4-S12. DOI:10.1089/dia.2019.2501 
25. Nathan DM, Genuth S, Lachin J, et al; Diabetes Control and Complications Trial Research Group.The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications. New Engl J Med. 1993;329(14):977-86.
26. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: Results from the structured testing program study. Diabetes Care. 2011;2(34):262-7. DOI:10.2337/dc10-1732 
27. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400-5.
DOI:10.2337/dc18-1444 
28. Bergenstal RM. Presented at the American Diabetes Association, 80th Scientific Sessions. June 12–16, 2020. Poster 21-LB.
29. Birjukova EV. The role of glycated hemoglobin in the diagnosis and improvement of the prognosis of diabetes mellitus. Medicinskij sovet. 2017;3:55-7 (in Russian).
30. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care. 2014;37(1):9-16. DOI:10.2337/dc13-2112 
31. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation / WHO Guidelines Approved by the Guidelines Review Committee. Geneva: World Health Organization, 2011. Available at: https://pubmed.ncbi.nlm.nih.gov/26158184/ Accessed: 18.11.2021.
32. Hashimoto K, Osugi T, Noguchi S, et al. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care. 2010;33(3):509-11. DOI:10.2337/dc09-1954 
33. Inaba M, Okuno S, Kumeda Y, et al. Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896-903. DOI:10.1681/ASN.2006070772 
34. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153-63. 
35. Ford ES, Cowie CC, Li C, et al. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3(1):67-73.
DOI:10.1111/j.1753-0407.2010.00100.x
36. Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018;41(11):2370-6. DOI:10.2337/dc18-1131 
37. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. DOI:10.1136/bmjdrc-2019-000991 
38. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019;2(21):81-5. DOI:10.1089/dia.2018.0310 
39. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13(4):614-26. DOI:10.1177/1932296818822496 
40. Ohigashi M, Osugi K, Kusunoki Y, et al. Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol. J Diabetes Investig. 2021;12(6):940-9. DOI:10.1111/jdi.13437 
41. Yoo JH, Choi MS, Ahn J, et al. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes. Diabetes Technol Ther. 2020;22(10):768-76. DOI:10.1089/dia.2019 
42. Kim MY, Kim G, Park JY, et al. The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes. Diabetes Technol Ther. 2021;23(6):434-42. DOI:10.1089/dia.2020.0599 
43. Lu J, Ma X, Shen Y, et al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. Diabetes Technol Ther. 2020;22(2):72-8. DOI:10.1089/dia.2019.0251 
44. Sheng X, Xiong G-H, Yu P-F, et al. The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform. Int J Endocrinol. 2020;2020:8879085. DOI:10.1155/2020/8879085 
45. Avari P, Uduku C, George D, et al. Differences for Percentage Times in Glycemic Range between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset. Diabetes Technol Ther. 2020;3(22):222-7. DOI:10.1089/dia.2019.0276 
46. Beck RW, Calhoun P, Kollman C. Use of continuous glucose monitoring as an outcome measure in clinical trials. Diabetes Technol Ther. 2012;10(14):877-82. DOI:10.1089/dia.2012.0079 
47. Суплотова Л.А., Судницына А.С., Романова Н.В., и др. Анализ времени нахождения в целевом диапазоне в зависимости от метода оценки уровня глюкозы. Медицинский Совет. 2021;7:46-55 [Suplotova LA, Sudnicyna AS, Romanova NV. Analysis of time in range depending on the method of assessing the glucose level. Medicinskij Sovet. 2021;7:46-55 (in Russian)]. DOI:10.21518/2079-701X-2021-7-46-55 
48. Fiallo-Scharer R. Eight-point glucose testing Versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. J Clin Endocrinol Metab. 2005;90(6):3387-91. DOI:10.1210/jc.2004-2510 

Л.А. Суплотова*1, А.С. Судницына2, Т.С. Душина1 

1 ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России, Тюмень, Россия;
2 ГБУЗ ТО «Областная клиническая больница №1», Тюмень, Россия
*suplotovala@mail.ru

________________________________________________

Lyudmila A. Suplotova*1, Anna S. Sudnitsyna2, Tatyana S. Dushina1

1 Tyumen State Medical University, Tyumen, Russia;
2 Regional Clinical Hospital №1, Tyumen, Russia
*suplotovala@mail.ru